Inside Big Pharma's AI Playbook: From Molecule Discovery to Clinical Trials

7 fronts where Big Pharma explores AI via partnerships and internal programs.

The traditional drug discovery process is among the most complex, costly, and time-consuming endeavors in science. Developing a single medicine might take over a decade of research and $2B in investments. This inefficiency stems largely from the linear structure of discovery: beginning with target identification, moving through hit discovery and lead optimization, followed by preclinical testing and long clinical trials. Each stage requires substantial resources, meticulous validation, and, too often, ends in disappointment.

Despite the extraordinary effort, the odds of success remain bleak. Only about 1 in 10 drug candidates entering clinical trials ultimately achieve regulatory approval, with failures most often linked to safety issues or insufficient efficacy. Even high-throughput screening (HTS), once celebrated as a breakthrough, delivers a discouraging hit rate of just 2.5%. Such low yields amplify delays, inflate costs, and exhaust resources.

In this article: Target Identification — Virtual Screening — De novo Design — Drug Repurposing — ADMET Prediction — AI-backed Synthesis Planning and Execution — Clinical Trials — (When) Will AI Cure the World?